Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Karger Country of Publication: Switzerland NLM ID: 0135054 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0232 (Electronic) Linking ISSN: 00302414 NLM ISO Abbreviation: Oncology Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, New York, Karger.
    • Subject Terms:
      Docetaxel/*therapeutic use ; Gastrectomy/*methods ; Neoplasm Recurrence, Local/*pathology ; Neoplasm Recurrence, Local/*therapy ; Oxonic Acid/*therapeutic use ; Stomach Neoplasms/*pathology ; Stomach Neoplasms/*therapy ; Tegafur/*therapeutic use; Aged ; Aged, 80 and over ; Chemotherapy, Adjuvant ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/blood ; Neoplasm Staging ; Nutrition Assessment ; Practice Guidelines as Topic ; Prognosis ; Retrospective Studies ; Stomach Neoplasms/blood ; Survival Analysis ; Treatment Outcome
    • Abstract:
      Background: The Japanese Gastric Cancer Treatment Guidelines recommend S-1 and S-1 plus docetaxel as postoperative chemotherapy for pathological stage II and III gastric cancer (GC). There is currently no strategy for using chemotherapy to treat high-risk recurrent pathological stage II/III. Previous studies reported that the several nutritional, immunological, and inflammatory markers examined the association with clinical outcomes after surgery for GC.
      Methods: Ninety patients with GC (stage II, n = 48; stage III, n = 42) for whom gastrectomy was performed at our institution between November 2009 and September 2018 were examined. Nutritional, immunological, and inflammatory markers were calculated from blood samples within 1 week before surgery.
      Results: The prognostic nutritional index (PNI) status correlated with the pathological stage and disease recurrence after surgery (p = 0.015 and p < 0.0001, respectively). Thirty-three patients had disease recurrence after gastrectomy (stage II, n = 11; stage III, n = 22). The PNI was significantly lower in the recurrent group than in the non-recurrent group (p = 0.0003). The PNI correlated with overall survival and recurrence-free survival after gastrectomy (p = 0.0021 and p = 0.0001, respectively). A multivariate analysis identified the PNI as an independent prognostic factor (p = 0.006).
      Conclusion: The PNI may be useful for predicting the outcomes of patients with pathological stage II/III GC and may contribute to the selection of an appropriate adjuvant chemotherapy regimen.
      (© 2021 S. Karger AG, Basel.)
    • Contributed Indexing:
      Keywords: Adjuvant chemotherapy; Disease recurrence; Gastric cancer; Prognostic nutritional index
    • Accession Number:
      0 (Drug Combinations)
      150863-82-4 (S 1 (combination))
      1548R74NSZ (Tegafur)
      15H5577CQD (Docetaxel)
      5VT6420TIG (Oxonic Acid)
    • Publication Date:
      Date Created: 20210307 Date Completed: 20210602 Latest Revision: 20210602
    • Publication Date:
      20240829
    • Accession Number:
      10.1159/000514572
    • Accession Number:
      33677434